← Back to Search

Other

BAIBA + Exercise for Obesity (LBC Trial)

N/A
Waitlist Available
Led By Chad M Kerksick, PhD
Research Sponsored by Lindenwood University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Free-living/uninhibited with use of ambulatory assistive devices and independent
Participants who are between 18 - 60 years of age
Must not have
Diagnosed with some form of immune disorder (i.e., HIV/AIDS)
Has liver disease or some form of clinically diagnosed hepatic impairment
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 weeks
Awards & highlights

Summary

This trial is testing whether a muscle-produced substance called BAIBA can help overweight and obese people lose weight and improve their health when combined with exercise. Participants will take different doses of BAIBA while following an exercise routine. The study aims to see if BAIBA can make the body better at using energy and burning fat. BAIBA has shown similar cardioprotective effects to exercise in previous studies.

Who is the study for?
This trial is for overweight and obese men and women, aged 18-60, with a BMI between >25.0 to <32.0 kg/m2 who are generally healthy without major diseases or disorders. Participants should be able to exercise safely and not be on certain medications like statins or have a history of substance abuse.
What is being tested?
The study tests the effects of adding L-BAIBA supplement to regular exercise on body composition, weight loss, glucose control, and cardiometabolic risk factors in adults struggling with obesity.
What are the potential side effects?
Since this trial involves an exercise regimen and dietary supplements (L-BAIBA), potential side effects may include muscle soreness, fatigue, gastrointestinal discomfort or allergic reactions to the supplement.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I can move around on my own, with or without help from devices like canes or walkers.
Select...
I am between 18 and 60 years old.
Select...
I am in good health, not overweight or mildly obese, and have no major health issues.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have been diagnosed with an immune disorder like HIV/AIDS.
Select...
I have liver disease or a diagnosed liver condition.
Select...
I have no physical limitations that would stop me from joining a fitness program.
Select...
I am currently receiving treatment for kidney disease or undergoing dialysis.
Select...
I have been diagnosed with or am being treated for thyroid disease.
Select...
I have a history of neurological conditions or diseases.
Select...
I have been diagnosed with diabetes.
Select...
I was hospitalized for a mental health issue in the last year.
Select...
I am currently taking medication for high cholesterol or high blood pressure.
Select...
I cannot swallow or digest food properly due to a GI tract issue.
Select...
I am not taking any weight loss drugs or supplements.
Select...
I have or am being treated for heart disease.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Fat Mass (4-compartment)
Secondary study objectives
4-Compartment Lean mass
Body Mass
Comprehensive Metabolic Panel
+8 more

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: 750 mg/day Mitoburn (L-BAIBA)Experimental Treatment1 Intervention
750 mg/day Mitoburn (L-BAIBA)
Group II: 1,500 mg/day Mitoburn (L-BAIBA)Experimental Treatment1 Intervention
1,500 mg/day Mitoburn (L-BAIBA)
Group III: PlaceboPlacebo Group1 Intervention
Placebo (Resistant Dextrin) (n=40)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Exercise
2016
Completed Phase 1
~820

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for obesity often target metabolic processes to enhance fuel metabolism and promote weight loss. GLP-1 receptor agonists, such as liraglutide, increase insulin secretion and slow gastric emptying, leading to reduced appetite and caloric intake. Metformin improves insulin sensitivity and reduces hepatic glucose production, aiding in weight management. Phentermine-topiramate combines an appetite suppressant with a medication that enhances energy expenditure. These mechanisms are crucial for obesity patients as they address the underlying metabolic dysfunctions, leading to more effective and sustainable weight loss.

Find a Location

Who is running the clinical trial?

Lindenwood UniversityLead Sponsor
18 Previous Clinical Trials
646 Total Patients Enrolled
Chad M Kerksick, PhDPrincipal InvestigatorLindenwood University
7 Previous Clinical Trials
248 Total Patients Enrolled

Media Library

Exercise (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05775016 — N/A
Obesity Research Study Groups: Placebo, 750 mg/day Mitoburn (L-BAIBA), 1,500 mg/day Mitoburn (L-BAIBA)
Obesity Clinical Trial 2023: Exercise Highlights & Side Effects. Trial Name: NCT05775016 — N/A
Exercise (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05775016 — N/A
Obesity Patient Testimony for trial: Trial Name: NCT05775016 — N/A
~9 spots leftby Oct 2025